GlaxoSmithKline

GSK reported a 19% drop in pre-tax profit to £1.9bn for July–September and Q3 revenue up 5% to £8.9bn, driven by specialty medicines while vaccine sales fell 2% (Shingrix -5%, Arexvy -24%). The company booked £318m of restructuring charges this quarter with total restructuring costs expected at £2.4bn and says more charges will follow as it pursues a three-year cost reduction plan. Investors were also concerned by the looming patent expiry for HIV drug dolutegravir even as GSK reiterates guidance, plans increased R&D, and targets over £40bn annual revenue by 2031. » More on theguardian.com

Three years ago GSK shares closed at £15.20; with the closing price on 09.10.2026 of £17.50, an investment of £100 would be worth £115.15 today (+15.15 percent). The calculation does not take stock splits or dividends into account. GSK most recently reached a market capitalization of £74.90 billion. » More on finanzen.net

If GSK shares had been bought for £1,000 on 28.09.2016 (price £20.69), the holding would now be 48.338 shares. At a closing price of £18.51 on 25.09.2026 the investment would be worth £894.74, a loss of 10.53%. The calculation does not take account of stock splits or dividends; market capitalization most recently £74.05 billion. » More on finanzen.net

Five years ago the closing price of GSK stock was £17.72; on 18 September 2026 the stock stood at £18.78. A £100 investment would have bought 5.643 shares then and would be worth £105.94 today, an increase of 5.94 percent. The calculation excludes stock splits and dividend payments; market capitalization most recently stood at £75.23 billion. » More on finanzen.net

GSK acquires a trispecific T‑cell engager (TCE) therapy from Chimagen and makes an upfront payment for worldwide rights; the deal could reach up to $750 million. The therapy targets treatment of multiple myeloma and is intended to improve tolerability and efficacy by binding to T cells and two tumor‑associated antigens. GSK plans to advance the program into phase‑1 studies in 2027; Chimagen will also receive additional development and commercialization milestone payments tied to success. » More on finanzen.net